The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

Dr. Francesco Maura is a co-author. Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance ...

Within the coming years, we expect to see claims expansion regarding using dd-cfDNA to monitor DSA+ patients, in the application of anti-CD38 drugs, as described above with daratumumab and felzartamab ...

GSK had great expectations for Blenrep, which was approved in 2020 for multiple myeloma patients who have received at least four prior therapies – including an anti-CD38 monoclonal antibody ...

Investigators were seeking a greater understanding of risk factors for hidradenitis suppurativa, a chronic inflammatory skin disease, concentrating on how it presents in skin of color.